BERLIN, Sept. 1, 2016 /PRNewswire/ -- At this year's Internationale Funkausstellung (IFA), taking place in Berlin, Germany from September 2-7, Royal Philips (NYSE: PHG, AEX: PHIA) is presenting innovations that empower people to live healthier lives across the health continuum, from prevention, to diagnosis, to treatment. During this year's show, Philips will highlight its vision for transforming the future of sleep. With more patients seeking medical care for sleep disorders1, the world is waking up to the challenge of healthy sleep, its impact on overall health and the need for a good night's rest.
During IFA, Philips will present innovations that help people get the rest they deserve, including the Dream Family solution designed to improve the sleep therapy experience for people with obstructive sleep apnea (OSA). More than 100 million people worldwide2 are estimated to have OSA, a serious condition that is treated with positive airway pressure (PAP) therapy. The Dream Family, comprised of the DreamWear mask, DreamStation PAP device and DreamMapper patient engagement app, is designed to engage sleep apnea patients with one of the most comfortable and effective therapies available. With the most comprehensive suite of connectivity options among all PAP therapy systems, Dream Family works as a connected solution to keep patients engaged in their therapy and linked to their care teams.
The components of the Dream Family were inspired by feedback from more than 900 patients, as well as insights from clinicians who treat sleep apnea. This input, combined with Philips' more than four decades of experience developing revolutionary patient-centric solutions, led to the award-winning design of the Dream Family. Since their launch in October 2015, DreamWear and DreamStation have been honored for excellence in design, including recent iF Design, Red Dot, Good Design Australia and Core77 accolades.
"Sleep therapy can be challenging, and our goal is to help people across the globe get a better night's rest – whether they live with a chronic sleep condition or are struggling to achieve eight hours a night," said John Frank, CEO, Sleep and Respiratory Care, Philips. "Next to nutrition and exercise, sleep is the third pillar of health and now we are looking to the future for all people who need help with improving their sleep quality. We intend to make good sleep possible for everyone."
In addition to the Dream Family, Philips will be showcasing two light therapy solutions designed to improve the experience of getting out of bed. These include:
Philips at IFA
The Philips press conference takes place on September 1 at 12:15pm in Hall 22, Messe Berlin. The live stream of the event can be seen at www.ifa.philips.com. Pieter Nota, CEO Personal Health businesses and Chief Marketing Officer at Philips, will be joined on stage by Chris Worp, Head of Business Group Home from Philips Lighting, and Kostas Vouzas, Senior Director Business EMEA at TP Vision.
For further information on the latest Philips innovations at IFA 2016 please visit www.ifa.philips.com, follow Philips at IFA on Twitter @PhilipsLiveFrom, or visit our additional social media channels on YouTube and LinkedIn.
For further information, please contact:
About Royal Philips
Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. The company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Headquartered in the Netherlands, Philips' health technology portfolio generated 2015 sales of EUR 16.8 billion and employs approximately 69,000 employees with sales and services in more than 100 countries. News about Philips can be found at www.philips.com/newscenter.
1 Ford ES, Wheaton AG, Cunningham TJ, Giles WH, Chapman DP, Croft JB. Trends in outpatient visits for insomnia, sleep apnea, and prescriptions for sleep medications among US adults: findings from the National Ambulatory Medical Care Survey 1999-2010.
3 Duijzer & Meesters THE EFFECTS OF LOW INTENSITY MONOCHROMATIC BLUE LIGHT TREATMENT COMPARED TO STANDARD LIGHT TREATMENT IN SUB- SYNDROMAL SAD; SLTBR Abstracts 2011, p.33
4 Giménez, M.C., Hessels, M., van de Werken, M., de Vries, B., Beersma, D.G.M., & Gordijn, M. C. M. (2010). Effects of artificial dawn on subjective ratings of sleep inertia and dim light melatonin onset. Chronobiology International, 27(6), 1219–1241. doi:10.3109/07420528.2010.496912
SOURCE Royal Philips